title: Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare.
abstract: Therapeutic antibodies are one of the major classes of medical countermeasures that can provide protection against potential bioweapons such as botulinum toxin. Although a broad array of antibodies are being evaluated for their ability to neutralize the toxin, there is little information that defines the circumstances under which these antibodies can be used. In the present study, an effort was made to quantify the temporal factors that govern therapeutic antibody use in a postchallenge scenario. Experiments were done involving inhalation administration of toxin to mice, intravenous administration to mice, and direct application to murine phrenic nerve-hemidiaphragm preparations. As part of this study, several pharmacokinetic characteristics of botulinum toxin and neutralizing antibodies were measured. The core observation that emerged from the work was that the window of opportunity within which postchallenge administration of antibodies exerted a beneficial effect increased as the challenge dose of toxin decreased. The critical factor in establishing the window of opportunity was the amount of time needed for fractional redistribution of a neuroparalytic quantum of toxin from the extraneuronal space to the intraneuronal space. This redistribution event was a dose-dependent phenomenon. It is likely that the approach used to identify the factors that govern postchallenge efficacy of antibodies against botulinum toxin can be used to assess the factors that govern postchallenge efficacy of medical countermeasures against any agent of bioterrorism or biological warfare.
authors.affiliation: Department of Medicine, Jefferson Medical College, 1020 Locust Street, Philadelphia, PA 119107, USA.
authors.forename: Fetweh H
authors.initials: FH
authors.lastname: Al-Saleem
authors.forename: Zidoon
authors.initials: Z
authors.lastname: Nasser
authors.forename: Rebecca M
authors.initials: RM
authors.lastname: Olson
authors.forename: Linsen
authors.initials: L
authors.lastname: Cao
authors.forename: Lance L
authors.initials: LL
authors.lastname: Simpson
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000494:pharmacology / Q000627:therapeutic use*; D057134:Antibodies, Neutralizing / Q000494:pharmacology / Q000627:therapeutic use*; D001694:Biological Warfare / Q000517:prevention & control; D023482:Bioterrorism / Q000517:prevention & control; D001905:Botulinum Toxins / Q000037:antagonists & inhibitors / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D051379:Mice; D009924:Organ Culture Techniques; D010791:Phrenic Nerve / Q000187:drug effects / Q000503:physiopathology; D020011:Protective Agents / Q000494:pharmacology / Q000627:therapeutic use; D011817:Rabbits; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000907:Antibodies, Bacterial; D057134:Antibodies, Neutralizing; D020011:Protective Agents; D001905:Botulinum Toxins